The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Abstract
BACKGROUND: Consensus panel recommendations regarding choice of an antipsychotic agent for schizophrenia differ markedly, but most consider second-generation antipsychotics (SGAs) as a homogeneous group. It has been suggested that SGAs seem falsely more efficacious than first-generation antipsychotics (FGAs) as a result of reduced efficacy due to use of a high-dose comparator, haloperidol. We performed (1) a meta-analysis of randomized efficacy trials comparing SGAs and FGAs, (2) comparisons between SGAs, (3) a dose-response analysis of FGAs and SGAs, and (4) an analysis of the effect on efficacy of an overly high dose of an FGA comparator. METHODS: Literature search of clinical trials between January 1953 and May 2002 of patients with schizophrenia from electronic databases, reference lists, posters, the Food and Drug Administration, and other unpublished data. We included 124 randomized controlled trials with efficacy data on 10 SGAs vs FGAs and 18 studies of comparisons between SGAs. Two of us independently extracted the sample sizes, means, and standard deviation of the efficacy data. RESULTS: Using the Hedges-Olkin algorithm, the effect sizes of clozapine, amisulpride, risperidone, and olanzapine were 0.49, 0.29, 0.25, and 0.21 greater than those of FGAs, with P values of 2 x 10-8, 3 x 10-7, 2 x 10-12, and 3 x 10-9, respectively. The remaining 6 SGAs were not significantly different from FGAs, although zotepine was marginally different. No efficacy difference was detected among amisulpride, risperidone, and olanzapine. We found no evidence that the haloperidol dose (or all FGA comparators converted to haloperidol-equivalent doses) affected these results when we examined its effect by drug or in a 2-way analysis of variance model in which SGA effectiveness is entered as a second factor. CONCLUSION: Some SGAs are more efficacious than FGAs, and, therefore, SGAs are not a homogeneous group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Statistical Methods for Meta-Analysis
Wasserman, S., Hedges, L. V., & Olkin, I. (1988) · Journal of Educational Statistics · doi:10.2307/1164953 · Cited by 10,326
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
Lehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
McAuley, L., Pham, B., Tugwell, P., & Moher, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02786-0 · Cited by 812
Arvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 803
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
Marder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 759
Self-citationTran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
Peuskens, J. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.6.712 · Cited by 551
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Brief Psychiatric Rating Scale
Overall, J. E., & Gorham, D. R. (2012) · PsycTESTS Dataset · doi:10.1037/t01554-000 · Cited by 495
Quetiapine in Patients With Schizophrenia: A High- and Low-Dose Double-blind Comparison With Placebo
Small, J. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180067009 · Cited by 478
Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Leucht, S., Pitschel-Walz, G., Engel, R. R., & Kissling, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.180 · Cited by 470
Purdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 469
Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410
Comparative Doses and Costs of Antipsychotic Medication
Davis, J. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770070088010 · Cited by 407
Self-citationVolavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., & Hamilton, S. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390
Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
Pickar, D. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050009001 · Cited by 354
Conley, R. R., & Mahmoud, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 334
Clozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.231 · Cited by 322
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306
The Risks and Benefits of Clozapine versus Chlorpromazine
CLAGHORN, J., HONIGFELD, G., ABUZZAHAB, F. S., WANG, R., STEINBOOK, R., TUASON, V., & KLERMAN, G. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198712000-00002 · Cited by 301
Claus, A., Bollen, J., Cuyper, H. D., Eneman, M., Malfroid, M., Peuskens, J., & Heylen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb01473.x · Cited by 295
Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.499 · Cited by 283
Beasley, C. M., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Tran, P. V., Blin, O., & Beuzen, J.-N. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00392-6 · Cited by 277
Borison, R. L., Arvanitis, L. A., & Milier, B. G. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00008 · Cited by 268
Buchanan, R. W., Breier, A., Kirkpatrick, B., Ball, P., & Carpenter, W. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.751 · Cited by 264
A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
Peuskens, J., & Link, C. G. G. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb10162.x · Cited by 251
Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia
Conley, R. R., Tamminga, C. A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., Hegerty, J., Love, R., Gounaris, C., & Zaremba, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.914 · Cited by 245
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001359.pub2 · Cited by 237
Risperidone: clinical safety and efficacy in schizophrenia.
Borison, R. L., Pathiraja, A., Diamond, B. I., & Meibach, R. C. (1992) · PubMed · Cited by 210
Breier, A. F., Malhotra, A. K., Su, T.-P., Pinals, D. A., Elman, I., Adler, C. M., Lafargue, R. T., Clifton, A., & Pickar, D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.294 · Cited by 208
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.179 · Cited by 207
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
Gerlach, J., Koppelhus, P., Helweg, E., & Monrad, A. (1974) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1974.tb09706.x · Cited by 197
Principles and practice of psychopharmacotherapy
Janicak, P. G. (2001) · Cited by 187
Risperidone versus typical antipsychotic medication for schizophrenia
Hunter, R., Kennedy, E., Song, F., Gadon, L., & Irving, C. B. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000440 · Cited by 183
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
Emsley, R. A., & Risperidone Working Group (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033413 · Cited by 180
Azorin, J.-M., Spiegel, R., Remington, G., Vanelle, J.-M., Péré, J.-J., Giguere, M., & Bourdeix, I. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1305 · Cited by 179
Kane, J. M., Marder, S. R., Schooler, N. R., Wirshing, W. C., Umbricht, D., Baker, R. W., Wirshing, D. A., Safferman, A., Ganguli, R., McMeniman, M., et al. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.965 · Cited by 178
Purdon, S. E., MALLA, A. K., Labelle, A., & Lit, W. (2001) · PubMed · Cited by 177
Høyberg, O. J., Fensbo, C., Lingjærde, O., Sloth‐Nielsen, M., Salvesen, I., & Remvig, J. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03480.x · Cited by 176
Emsley, R. A., Raniwalla, J., Bailey, P. J., & Jones, A. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00001 · Cited by 175
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens, J., Bech, P., Möller, H.-J., Bale, R., Fleurot, O., & Rein, W. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00075-x · Cited by 170
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
van Kammen, D. P., McEvoy, J. P., Targum, S. D., Kardatzke, D. R., & Sebree, T. B. (1996) · Psychopharmacology · doi:10.1007/bf02245618 · Cited by 157
Atypical antipsychotics: are some more atypical than others?
Remington, G. J., & Kapur, S. (2000) · Psychopharmacology · doi:10.1007/s002130050017 · Cited by 154
A 28-Week Comparison of Ziprasidone and Haloperidol in Outpatients With Stable Schizophrenia
Hirsch, S. R., Kissling, W., Bäuml, J., Power, A., & O'Connor, R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0609 · Cited by 152
Risperidone in Treatment-Refractory Schizophrenia
Wirshing, D. A., Marshall, B. D., Green, M. F., Mintz, J., Marder, S. R., & Wirshing, W. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1374 · Cited by 148
Copolov, D., Link, C. G. G., & Kowalcyk, B. B. (2000) · Psychological Medicine · doi:10.1017/s0033291799001476 · Cited by 144
Puech, A. J., Fleurot, O., Rein, W., & Amisulpride Study Group (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb10044.x · Cited by 143
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
Colonna, L., Saleem, P., Dondey-Nouvel, L., & Rein, W. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015010-00002 · Cited by 139
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol
Möller, H. ‐., Boyer, P., Fleurot, O., & Rein, W. (1997) · Psychopharmacology · doi:10.1007/s002130050361 · Cited by 139
The Texas Medication Algorithm Project (TMAP) Schizophrenia Algorithms
Miller, A. L., Chiles, J. A., Chiles, J. K., Crismon, M. L., Rush, A. J., & Shon, S. P. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1002 · Cited by 136
Trân, P. V., Dellva, M. A., Tollefson, G. D., Wentley, A. L., & Beasley, C. M. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.172.6.499 · Cited by 135
Wetzel, H., Gründer, G., Hillert, A., Philipp, M., Gattaz, W. F., Sauer, H., Adler, G., Schröder, J., Rein, W., & Benkert, O. (1998) · Psychopharmacology · doi:10.1007/s002130050614 · Cited by 129
Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials
Bollini, P., Pampallona, S., Orza, M. J., Adams, M. E., & Chalmers, T. C. (1994) · Psychological Medicine · doi:10.1017/s003329170002729x · Cited by 129
Klieser, E., Lehmann, E., Kinzler, E., Wurthmann, C., & HEINRICH, K. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00008 · Cited by 121
Lee, M., Jayathilake, K., & Meltzer, H. Y. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00145-5 · Cited by 120
Blin, O., Azorin, J. M., & Bouhours, P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00007 · Cited by 117
Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.
Miller, D. D., Fleming, F. J., Holman, T. L., & Perry, P. J. (1994) · PubMed · Cited by 115
Meyer‐Lindenberg, A., Gruppe, H., Bauer, U., Lis, S., Krieger, S., & Gallhofer, B. (1997) · Pharmacopsychiatry · doi:10.1055/s-2007-979481 · Cited by 112
Clozapine Treatment of Outpatients With Schizophrenia: Outcome and Long-Term Response Patterns
Breier, A. F., Buchanan, R. W., Irish, D., & Carpenter, W. T. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.10.1249 · Cited by 104
Carrière, P., Bonhomme, D., & Lempérière, T. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00401-6 · Cited by 100
The Effects of Olanzapine on the 5 Dimensions of Schizophrenia Derived by Factor Analysis
Davis, J. M., & Chen, N. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1003 · Cited by 98
Self-citationČešková, E., & Švestka, J. (1993) · Pharmacopsychiatry · doi:10.1055/s-2007-1014355 · Cited by 97
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Tancer, M. E., & Uhde, T. W. (1997) · PubMed · Cited by 97
Chouinard, G., & Albright, P. S. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00010 · Cited by 97
HUTTUNEN, M. O., Piepponen, P. T., Rantanen, H., Larmo, I., Nyholm, R., & Raitasuo, V. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09781.x · Cited by 95
Hamilton, S. H., Edgell, E. T., Revicki, D. A., & Breier, A. F. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015050-00001 · Cited by 93
An example of European multicenter trials: multispectral analysis of clozapine.
Fischer-Cornelssen, K. A., & Uj, F. (1976) · PubMed · Cited by 91
Cost-effectiveness of Clozapine in Patients With High and Low Levels of Hospital Use
Rosenheck, R. A. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.565 · Cited by 86
Double-Blind Study of Clozapine Dose Response in Chronic Schizophrenia
Simpson, G. M., Josiassen, R. C., Stanilla, J. K., de León, J., Nair, C., Abraham, G., Odom-White, A., & Turner, R. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1744 · Cited by 84
Clozapine in China: a review and preview of US/PRC collaboration
Potter, W. Z., Ko, G. N., Zhang, L. D., et al. (1989) · Psychopharmacology · doi:10.1007/bf00442568 · Cited by 82
Delcker, A., Schoon, M., Oczkowski, B., & Gaertner, H. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014494 · Cited by 79
Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
Wahlbeck, K., Cheine, M. V., Tuisku, K., Ahokas, A., Joffe, G., & Rimón, R. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00118-4 · Cited by 76
Daniel, D. G., Wozniak, P., Mack, R. J., & McCarthy, B. G. (1998) · PubMed · Cited by 74
Gelenberg, A. J., & Doller, J. C. (1979) · PubMed · Cited by 70
Min, S. K., Rhee, C. S., Kim, C. E., et al. (1993) · Yonsei Medical Journal · doi:10.3349/ymj.1993.34.2.179 · Cited by 68
Cooper, S. J., Tweed, J. A., Raniwalla, J., Butler, A., & Welch, C. P. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101003218.x · Cited by 67
Saletu, B., Kufferle, B., Grünberger, J., ldes, P. F. O., Topitz, A., & Anderer, P. (2008) · Neuropsychobiology · doi:10.1159/000119075 · Cited by 67
Hong, C.-J., Chen, J., Chiu, H.-J., & Sim, C. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00001 · Cited by 61
Clinical Profile of an Atypical Antipsychotic: Risperidone
Davis, J. M., & Chen, N. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006925 · Cited by 61
Self-citationA double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia
McCreadie, R. G., Todd, N. A., Livingston, M., et al. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb06300.x · Cited by 59
Ishigooka, J., Inada, T., & Miura, S. (2001) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2001.00882.x · Cited by 56
Martin, S. D., Löo, H., Peuskens, J., Thirumalai, S., Giudicelli, A., Fleurot, O., Rein, W., & for the SOLIANOL Study Group (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001128 · Cited by 54
Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Ww, F., Barnas, C., Stuppäck, C., Unterweger, B., Miller, C., & Hinterhuber, H. (1989) · PubMed · Cited by 53
Zhang, X.-Y., Zhou, D. F., Cao, L., Zhang, P.-Y., Wu, G. Y., & Shen, Y. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200111000-00002 · Cited by 50
Bouchard, R.-H., Mérette, C., Pourcher, E., Demers, M., Villeneuve, J., Roy‐Gagnon, M., Gauthier, Y., Cliche, D., Labelle, A., Filteau, M., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00002 · Cited by 47
Rosenheck, R. A., Cramer, J. A., Xu, W., Grabowski, J., Douyon, R., Thomas, J. V., Henderson, W., & Charney, D. S. (1998) · Europe PMC (PubMed Central) · Cited by 39
Bernardo, M., Parellada, E., Lomeña, F., Catafau, A. M., Font, M., Gómez, J. C., López-Carrero, C., Gutiérrez, F., Pavı́a, J., & Salamero, M. (2001) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(01)00085-3 · Cited by 35
Risperidone: How Good Is the Evidence for Efficacy?
Mattes, J. A. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.1.155 · Cited by 33
Laux, G., KIieser, E., Schröder, H. G., Dittmann, V., Unterweger, B., Schutert, H., König, P., Schöny, H. W., Bunse, J., & Beckmann, H. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05303.x · Cited by 30
Klieser, E., Strauß, W. H., & Lemmer, W. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05836.x · Cited by 30
DeSilva, P., Fenton, M., & Rathbone, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001948.pub2 · Cited by 27
Keks, N. A., McGrath, J. J., Lambert, T. J. R., Catts, S. V., Vaddadi, K. S., Burrows, G. D., Varghese, F. T. N., George, T. P., Hustig, H., Burnett, P., et al. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01607.x · Cited by 27
A double‐blind multicentre comparison of remoxipride, at two dose levels, and haloperidol
Patris, M., Agussol, P., Alby, J. M., Brion, S., Burnat, G., Castelnau, D., Deluermoz, S., Dufour, H., Ferreri, M., Goudemand, M., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05294.x · Cited by 26
Remoxipride and haloperidol in schizophrenia: a double‐blind multicentre study.
Ahlfors, U. G., Rimón, R., Appelberg, B., Hagert, U., Harma, P., Katila, H., Mahlanen, A., Mehtonen, O., Naukkarinen, H., Outakoski, J., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05298.x · Cited by 24
Gattaz, W. F., Diehl, A., Geuppert, M. S., Hubrich-Ungureanu, P., Schmitt, A., Linde, I., Maras, A., & Dittmann, R. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832684 · Cited by 23
Remoxipride versus thioridazine in elderly psychotic patients
Phanjoo, A. L., & Link, C. G. G. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05314.x · Cited by 22
Dawkins, K., Lieberman, J. A., Lebowitz, B. D., & Hsiao, J. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033387 · Cited by 22
Pflug, B., Bartels, M., Bauer, H., Bunse, J., Gallhofer, B., Haas, S., Kanzow, W. T. H., Klieser, E., Kufferle, B., Stein, D., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05307.x · Cited by 21
Comparison of Efficacy of Zotepine and Thiothixene in Schizophrenia in a Double-blind Study
Sarai, K., & Okada, M. (1987) · Pharmacopsychiatry · doi:10.1055/s-2007-1017128 · Cited by 21
Mendlewicz, J., Bleeker, E. D., Cosyns, P. R., Deleu, G., Lotstra, F., Masson, A., Mertens, C., Parent, M., Peuskens, J., Suy, E., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05306.x · Cited by 19
A double‐blind comparative multicentre study of remoxipride and haloperidol in schizophrenia
Lindström, L., Wiesekjren, I. ‐., Struwe, G., Kristjansson, E., Akselsorn, S., Arthur, H., Andersen, T., Lindgren, S., Norman, Q., Naimell, L., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05304.x · Cited by 19
Efficacy and safety of sertindole in a trial of schizophrenic patients
Zborowski, J. V., Schmitz, P., Staser, J., O'Neil, J., Giles, K., Wallin, B., Sebree, T. B., & Tamminga, C. A. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)94656-h · Cited by 18
A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia
Andersen, J., Kørner, A., Østergård, P., Fensbo, C., Birket‐Smith, M., Thiesen, S., Hansen, N. R., Fogh, M., Kristensen, M., Møller‐Nielsen, E. M., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05299.x · Cited by 15
Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder
Potkin, S. G., Kujawa, M. J., Carson, W. H., Saha, A. R., Ali, M. D. A., & Ingenito, G. G. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80511-x · Cited by 15
Remoxipride and haloperidol in the acute phase of schizophrenia: a double‐blind comparison
Deo, R., Soni, S. D., Rastogi, S., Levine, S., PIant, I., Edwards, J. G., Mitchell, M. J., & Chanas, A. C. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05302.x · Cited by 14
The treatment of negative symptoms: a clinical and methodological study
Lapierre, Y. D., Angus, C., Awad, A. G., Saxena, B., Jones, B., Williamson, P., Vincent, P., Carle, R., Lavallée, Y. J., Manchanda, R., et al. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199903000-00007 · Cited by 13
A Double Blind Comparison of Amisulpride vs. Haloperidol in Acute Schizophrenic Patients
Klein, H., Dieterle, D., Rüther, E., Eben, E., Nedopil, N., & Hippius, H. (1985) · Springer eBooks · doi:10.1007/978-1-4613-2363-1_106 · Cited by 12
A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
Lapierre, Y. D., Ancill, R. J., Awad, G. A., Bakish, D., Beaudry, P., Bloom, D., Chandrasena, R. D., Das, M., Durand, C., & Elliott, D. (1992) · PubMed Central · Cited by 10
Hebenstreit, G. F., Laux, G., Schubert, H., Beckmann, H., Amman, J. M. A., Bunse, J., Eikmeier, G., Geretsegger, C., Kanitz, R.-D., Kanzow, W. T. H., et al. (1991) · Pharmacopsychiatry · doi:10.1055/s-2007-1014460 · Cited by 10
A double‐blind comparative study of remoxipride and haloperidol in acute schizophrenia.
den Boer, J. A., Ravelli, D. P., Huisman, J., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05300.x · Cited by 9
The efficacy of zotepine in schizophrenia: A meta-analysis of BPRS and improvement scale scores
Butler, A. (2000) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500052048460 · Cited by 6
Cited by
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citationSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Metadata
- Authors
- Davis, J. M., Chen, N., & Glick, I. D.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2003-06-01
- Volume
- 60
- Issue
- 6
- Pages
- 553
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2041474698
- Cited by
- 1,034
- References
- 129
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.